

Mouse H-2Db Antibody

PE (R-phycoerythrin)

Hybridoma Monoclonal Antibody

Product Information

Product No.: B343

Clone: B22/249

Isotype: Mouse IgG2a k

Storage: Sterile 2° to 8°C

Product Description

Specificity:

B22.249.R1 activity is directed against mouse H-2Db

Antigen Distribution:

H-2Db is expressed on the cell surface of lymphocytes

Background:

H-2, the murine major histocompatibility complex (MHC), is composed of a diverse group of antigens divided into class I and II proteins that function in immune response¹. H-2Db is a class I MHC cell surface protein. MHC class I molecules bind peptides generated by the degradation of cytosolic proteins, and then display those peptides on the cell surface. Generally, these peptides are derived from normal metabolism, but they can also be derived from foreign proteins during viral infection or allotransplantation. For example, H-2Db plays a role in human papillomavirus infection². When peptides are recognized as foreign, cytotoxic T lymphocytes specific to the MHC class I-peptide complex kill the presenting cell¹.

B22-249.R1 was generated by immunizing mice with spleen cells from allogeneic mice using the combination BSLB/k anti-C57BL/6³. Spleen cells of the recipient mouse were hybridized with the P3-NS 1-Ag4 myeloma cell line and screened using cytotoxic and hemagglutination assays. B22-249.R1 is also known as H-2.m2 in the literature⁴.

Known Reactivity Species:

Mouse

Format:

PE (R-phycoerythrin)

Immunogen:

Mouse H-2Db

Formulation

This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Storage and Stability

This R-phycoerythrin (R-PE) conjugate is stable when stored at 2° to 8°C

Do not freeze

Other Applications Reported in Literature:

FC

Product Datasheet www.leinco.com

Leinco Technologies, Inc. excellence in early discovery research™

Country of Origin

USA

References

- 1) Yoshida R. Adv Immunol. 124:207-247. 2014.
- 2) Peng S, Mattox A, Best SR, et al. Cancer Immunol Immunother. 65(3):261-271. 2016.
- 3) Hammerling GJ, Hammerling U, and Lemke HL. Immunogenetics. 8:433. 1979.
- 4) Klein J, Huang HJS, Lemke H, et al. Immunogenetics. 8:419. 1979.
- 5) Maloy WL, Hämmerling G, Nathenson SG, et al. J Immunol Methods. 37(3-4):287-299. 1980.
- 6) Maloy WL, Coligan JE. Immunogenetics. 16(1):11-22. 1982.
- 7) Melino M, Nichols E, Strausser H, et al. J Immunol. 129:222. 1982.
- 8) Shapiro LH, Dugan ES, Neiderhuber JE. J Exp Med. 162(5):1477-1493. 1985.